Advertisement

Advertisement
Breast Cancer

TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer

The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard...

Breast Cancer

From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals...

Issues in Oncology

AACR Annual Cancer Progress Report Highlights Scientific Advances Against Cancer, Challenges and Opportunities Ahead

The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)...


Advertisement
Leukemia

Value of Some Established Treatment Practices in Chronic Myeloid Leukemia

The introduction of imatinib mesylate, the first BCR::ABL1 tyrosine kinase inhibitor, as a treatment of Philadelphia chromosome (Ph)-positive chronic myeloid leukemia...

Bladder Cancer

Two Studies Show Improved Survival With Novel Front-Line Combinations in Advanced Urothelial Carcinoma

Two phase III trials presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress 2023 showed an overall survival...

Advertisement




Immunotherapy
Issues in Oncology

Charlotte E. Ariyan, MD, PhD, on Metastasectomy After Immunotherapy: Is It Effective?

Issues in Oncology

Predictors of Emergency Department Visits After a New Diagnosis of Cancer

In a retrospective cohort study reported in JCO Oncology Practice, Hong et al found that prior frequent emergency department use was the strongest predictor of postdiagnosis emergency department visits among patients with a new diagnosis of cancer. Study Details The study involved data from...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Immunotherapy
Issues in Oncology

Charlotte E. Ariyan, MD, PhD, on Metastasectomy After Immunotherapy: Is It Effective?

Kidney Cancer
Immunotherapy

Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma

In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...

Gynecologic Cancers
Cost of Care

Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity

In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Melinda L. Telli, MD, on Breast Cancer: Neoadjuvant Talazoparib for Early HER2-Negative Disease

Breast Cancer
Immunotherapy

Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MD, and colleagues, updated results of the phase II TBCRC026 trial indicate an association of early F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (F-18 FDG PET/CT) maximum standardized uptake value...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter